Prolonged continuous infusion of low-dose rIL-2.

por Janssen, R. A., Buter, J., The, T. H., Mulder, N. H., de Leij, L.
Publicado 1994

Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.

por Janssen, R. A., Kroesen, B. J., Buter, J., Mesander, G., Sleijfer, D. T., The, T. H., Mulder, N. H., de Leij, L.
Publicado 1995

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

por Kroesen, B. J., Buter, J., Sleijfer, D. T., Janssen, R. A., van der Graaf, W. T., The, T. H., de Leij, L., Mulder, N. H.
Publicado 1994

Salvage surgery in post-chemoradiation laryngeal and hypopharyngeal carcinoma: outcome and review

por PUTTEN, L., BREE, R., DOORNAERT, P.A., BUTER, J., EERENSTEIN, S.E.J., RIETVELD, D.H.F., KUIK, D.J., LEEMANS, C.R.
Publicado 2015

Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis

por Holla, F. K., Postma, T. J., Blankenstein, M. A., van Mierlo, T. J. M., Vos, M. J., Sizoo, E. M., de Groot, M., Uitdehaag, B. M. J., Buter, J., Klein, M., Reijneveld, J. C., Heimans, J. J.
Publicado 2016

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced...

por Garrett, C R, Siu, L L, El-Khoueiry, A, Buter, J, Rocha-Lima, C M, Marshall, J, LoRusso, P, Major, P, Chemidlin, J, Mokliatchouk, O, Velasquez, L, Hayes, W, Feltquate, D, Syed, S, Ford, S, Kollia, G, Galbraith, S, Nuyten, D S A
Publicado 2011